Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01089283|
Recruitment Status : Unknown
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : March 18, 2010
Last Update Posted : March 18, 2010
Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation.
Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group.
The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute.
The examination results will be given to the participants by a doctor from the neurology department.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||March 2011|
Parkinson patients that carry mutation on LRRK2 gene
Parkinson patients that carry mutation on GBA gene
Parkinson patients that don't carry mutation on LRRK2 or GBA genes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01089283
|Contact: Einat Even-sapir, PhD, MD||972-3-6974444 ext email@example.com|
|Contact: Ayelet Kurzband, BA||972-3-6974444 ext firstname.lastname@example.org|
|Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel|
|Contact: Einat Even-Sapir, MD, PhD 972-3-6974444 ext 3536 Evensap@tasmc.health.gov.il|
|Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 email@example.com|
|Sub-Investigator: Hedva Lerman, MD|
|Sub-Investigator: Nir Giladi, PhD, MD|
|Sub-Investigator: Anat Milerman|
|Principal Investigator:||Einat Even-Sapir, MD, PhD||Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|